Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

PHASE3TerminatedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

April 26, 2022

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Adenovirus Infection
Interventions
DRUG

Posoleucel

Administered as 2-4 milliliter infusion, visually identical to placebo

DRUG

Placebo

Administered as 2-4 milliliter infusion, visually identical to Posoleucel

Trial Locations (47)

165

Ospedale Pediatrico Bambino Gesù, Roma

10032

New York Presbyterian Hospital, New York

10065

Memorial Sloan Kettering Cancer Center, New York

10126

Ospedale Regina Margherita, Torino

20010

Children's National Medical Center, Washington D.C.

20132

IRCCS Ospedale San Raffaele, Milan

20900

Fondazione IRCCS San Gerardo dei Tintori, Monza

27100

Fondazione IRCCS Policlinico San Matteo, Pavia

27710

Duke University Medical Center, Durham

28046

Hospital Universitario La Paz, Madrid

32611

University of Florida (UF) - Gainesville, Gainesville

35128

Azienda Ospedaliera di Padova, Padua

41685

Sahlgrenska University Hospital, Gothenburg

44195

Cleveland Clinic, Cleveland

46026

Hospital Universitari i Politecnic La Fe, Valencia

55455

University of Minnesota, Minneapolis

60611

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

63110

Washington University School of Medicine in St. Louis, St Louis

73104

University of Oklahoma, Oklahoma City

75390

University of Texas Southwestern, Dallas

76104

Cook Children's Medical Center, Fort Worth

80045

Children's Hospital Colorado - Center for Cancer and Blood Disorders, Aurora

80123

A.O.R.N. Santobono-Pausilipon, Napoli

81432

Intermountain HealthCare - Primary Children's Hospital, Salt Lake City

85016

Phoenix Children's Hospital, Phoenix

85234

MD Anderson Cancer Center, Gilbert

90095

University of California, Los Angeles (UCLA), Los Angeles

91010

City of Hope, Duarte

92123

University of California, San Diego - Rady Children's Hospital, San Diego

94303

Lucile Packard Children's Hospital - Stanford University, Palo Alto

98101

Seattle Children's Hospital, Seattle

02215

Dana-Farber Cancer Institute, Boston

07601

Hackensack University Medical Center, Hackensack

M5G 1X8

The Hospital for Sick Children (SickKids), Toronto

H3T 1C5

CHU Sainte-Justine, Montreal

1-37126

Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento, Verona

08035

Hospital Universitario Vall d'Hebron, Barcelona

221 85

Skane University Hospital Lund, Lund

171 64

Karolinska University Hospital, Solna

B4 6NH

Birmingham Children's Hospital, Birmingham

BS2 8BJ

Bristol Royal Hospital for Children, Bristol

G51 4TF

Royal Hospital for Children - Glasgow, Glasgow

NW1 2PG

University College London Hospital, London

W2 1NY

St. Mary's Hospital, Paddington, London

WC1n 3JH

Great Ormond Street Hospital for Children, London

M13 9WL

Royal Manchester Children's Hospital, Manchester

S10 2TH

Sheffield Children's NHS Foundation Trust, Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AlloVir

INDUSTRY

NCT05179057 - Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation | Biotech Hunter | Biotech Hunter